GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Yubo International Biotech Ltd (OTCPK:YBGJ) » Definitions » ROC (Joel Greenblatt) %

Yubo International Biotech (Yubo International Biotech) ROC (Joel Greenblatt) % : -233.38% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Yubo International Biotech ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Yubo International Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -233.38%.

The historical rank and industry rank for Yubo International Biotech's ROC (Joel Greenblatt) % or its related term are showing as below:

YBGJ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -180.71   Med: -96.32   Max: -50.79
Current: -134.62

During the past 4 years, Yubo International Biotech's highest ROC (Joel Greenblatt) % was -50.79%. The lowest was -180.71%. And the median was -96.32%.

YBGJ's ROC (Joel Greenblatt) % is ranked worse than
72.94% of 850 companies
in the Medical Devices & Instruments industry
Industry Median: -0.85 vs YBGJ: -134.62

Yubo International Biotech's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Yubo International Biotech ROC (Joel Greenblatt) % Historical Data

The historical data trend for Yubo International Biotech's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yubo International Biotech ROC (Joel Greenblatt) % Chart

Yubo International Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-180.71 -82.69 -50.79 -109.94

Yubo International Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -94.56 -124.46 2.28 -231.58 -233.38

Competitive Comparison of Yubo International Biotech's ROC (Joel Greenblatt) %

For the Medical Instruments & Supplies subindustry, Yubo International Biotech's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yubo International Biotech's ROC (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Yubo International Biotech's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Yubo International Biotech's ROC (Joel Greenblatt) % falls into.



Yubo International Biotech ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.08 + 0.215 + 0.138) - (2.685 + 0.434 + -4.4408920985006E-16)
=-2.686

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.115 + 0.212 + 0.071) - (2.892 + 0.426 + 0.00099999999999989)
=-2.921

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Yubo International Biotech for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.636/( ( (0.767 + max(-2.686, 0)) + (0.635 + max(-2.921, 0)) )/ 2 )
=-1.636/( ( 0.767 + 0.635 )/ 2 )
=-1.636/0.701
=-233.38 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Yubo International Biotech  (OTCPK:YBGJ) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Yubo International Biotech ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Yubo International Biotech's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Yubo International Biotech (Yubo International Biotech) Business Description

Traded in Other Exchanges
N/A
Address
31 Xishiku Avenue, Room 105, Building 5, Xicheng District, Beijing, CHN, 100034
Yubo International Biotech Ltd is a technology company focused on the research and development and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of nebulizers containing frozen tubes with medical fluid and from the sale of oral liquids health products. The nebulizers are sold directly to consumers on its online e-commerce platform.
Executives
Lina Liu 10 percent owner, officer: CFO, Treasurer and Secretary MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Focus Draw Group Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Boao Biotech Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Flydragon International Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Chinaone Technology Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Bai Zhihui director MAGNU-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Wang Jun director, officer: President and CEO MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Wang Yang director MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Joel S Kanter director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Jonathan Adereth director C/O MEDIVISION, PO BOX 45 INDUSTRIAL PARK, YOKNEAM ISRAEL
Magna Acquisition Llc 10 percent owner 8000 TOWERS CRESCENT DRIVE, SUITE 1070, VIENNA VA 22182
Kenneth C Riscica officer: Treasurer and Secretary C/O MAGNA-LAB INC., 6800 JERICHO TURNPIKE, SUITE 120W, SYOSSET NY 11791
Lawrence A Minkoff director, officer: Chairman, President, CSO C/O MAGNA-LAB INC, 6800 JERICHO TURNPIKE, SUITE 120W, SYOSSET NY 11791
Jerome M Feldman director C/O MAGNA-LAB INC, 6800 JERICHO TURNPIKE SUITE 120W, SYOSSET NY 11791
Seymour Kessler director C/O MAGNA-LAB INC., 6800 JERICHO TURNPIKE #120W, SYOSSET NY 11791

Yubo International Biotech (Yubo International Biotech) Headlines

No Headlines